{
  "harness": "sj-harness 0.6.0",
  "job": "job:4ae5ac9ff47df3fbcb05b480b4533dea",
  "kind": "domain_review",
  "bundle": "sha256:06169a44cf4f7a1ea4824d16d774cf7224b19fc20d9267747491a6d979b7390e",
  "claims": [
    {
      "local_id": "C1",
      "claim_id": "claim:9ab2ee87867ecfaa29ff37e068c05b80fe2b1437ed994bc43bb669c9f2844e44",
      "verdict": "minor_issues",
      "significance": "known",
      "reason": "Cure-vs-containment trade-off is established (Hansen et al. 2017 PLOS Biol; Hansen & Read 2020); de novo-only regime is a small-population artifact (N0=500), since resistant mutants pre-exist at clinical sizes (Komarova & Wodarz 2005; Iwasa et al. 2006); no sensitivity analysis."
    },
    {
      "local_id": "C2",
      "claim_id": "claim:6cfbc87e969808428086a99fd400bf2da41467dedccb79240388b966a34a61fc",
      "verdict": "minor_issues",
      "significance": "known",
      "reason": "Modest TTP gain with dose sparing under pre-existing resistance is the standard result (Zhang 2017, Gallaher 2018); magnitude depends on N0/K, progression threshold and turnover (Viossat & Noble 2021), none varied or cited."
    },
    {
      "local_id": "C3",
      "claim_id": "claim:8779d7de627dda259610a2af1294230ab73bd12716fc94d4dbaec984e8a0b5a3",
      "verdict": "major_issues",
      "significance": "known",
      "reason": "Generalises one low-turnover, N0/K=0.25 setting; Strobl et al. 2021 (Cancer Res) and Viossat & Noble 2021 show crowding without a resistance cost can give substantial delay with higher turnover or density; neither cited."
    }
  ]
}